Seroatlas · Human Serome Atlas

LYRM9

LYR motif-containing protein 9

Also known as: C17orf108, HSD24, LYRM9_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
A8MSI8
Gene
LYRM9
Ensembl
ENSG00000232859
Chromosome
17
Canonical length
78 aa
Protein class
Predicted intracellular proteins

OverviewNCBI Gene

Located in mitochondrion. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

78 residues, UniProt reviewed canonical sequence.

>A8MSI8|LYRM9
     1  MAPLPGAELV RRPLQLYRYL LRCCQQLPTK GIQQHYKHAV RQSFRVHSDE DNPERIQQII
    61  KRAIEDADWI MNKYKKQN

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYRM9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.37
Highest tissue expression
73 nTPM

Expression across tissuesHPA

Tissue

  • basal ganglia: 73 nTPM
  • cerebral cortex: 71 nTPM
  • amygdala: 63 nTPM
  • hippocampal formation: 56 nTPM
  • hypothalamus: 47 nTPM
  • adrenal gland: 40 nTPM

Single-cell type

  • oocytes: 9.2 nCPM
  • hepatic stellate cells: 6.5 nCPM
  • early primary spermatocytes: 5.3 nCPM
  • epididymal clear cells: 4.1 nCPM
  • fallopian tube ciliated cells: 3.9 nCPM
  • differentiating spermatogonia: 3.4 nCPM

Immune cell

  • naive CD4 T-cell: 15 nTPM
  • naive B-cell: 11 nTPM
  • naive CD8 T-cell: 10 nTPM
  • T-reg: 9.5 nTPM
  • memory CD4 T-cell: 8.1 nTPM
  • neutrophil: 8 nTPM

Brain region

  • hypothalamus: 60 nTPM
  • cerebral cortex: 56 nTPM
  • hippocampal formation: 51 nTPM
  • basal ganglia: 51 nTPM
  • amygdala: 47 nTPM
  • medulla oblongata: 36 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.62
gnomAD pLI
0.01
gnomAD missense Z
0.33
DepMap mean gene effect
-0.07
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Cellular components

Protein domainsUniProt · Pfam · InterPro

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYRM9 as an antibody target. Whether an autoantibody or antibody against LYRM9 could matter depends on whether native LYRM9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYRM9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label LYRM9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/LYRM9. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...